Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Respir Med ; 109(4): 463-74, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25749641

ABSTRACT

BACKGROUND: Although exercise is a vital component of the therapy prescribed to individuals with cystic fibrosis (CF), it is not a priority due to a finite amount of treatment time and the view that exercise is not as beneficial as pharmacological treatments by many individuals with CF. We sought to compare the therapeutic benefits of exercise and their prescribed bronchodilator albuterol. METHODS: CF (n = 14) and healthy (n = 16) subjects completed three visits, a baseline screening with VO2 max test and two treatment visits. On the two treatment visits, subjects completed spirometry and diffusing capacity of the lungs for nitric oxide (DLNO) maneuvers either at baseline, 60, and 110 min post-albuterol administration, or at baseline and the midway point of three separate 15 min exercise bouts at low, moderate and vigorous intensity (25, 50 and 65% of the maximum workload, respectively). RESULTS: With moderate exercise the increase in DLNO was double (39 ± 8 vs 15  ± 6% change) and the level of bronchodilation similar (23% change) when compared to 110 min post-albuterol in individuals with CF. During exercise FVC became reduced (-309 ± 66 mL with moderate exercise) and the increase in FEV1 was attenuated (103 ± 39 vs 236 ± 58 mL, exercise vs. albuterol) when compared with the response to albuterol in individuals with CF. Epinephrine (EPI) release increased 39, 72 and 144% change with low, moderate and vigorous intensity exercise respectively for individuals with CF, but this increase was blunted when compared to healthy subjects. CONCLUSION: Our results suggest that moderate intensity exercise is the optimal intensity for individuals with CF, as low intensity exercise increases EPI less than 50% and vigorous intensity exercise is over taxing, such that airflow can be restricted. Although the duration of the beneficial effect is uncertain, exercise can promote greater improvements in gas diffusion and comparable bronchodilation when compared to albuterol.


Subject(s)
Albuterol/administration & dosage , Cystic Fibrosis , Exercise Therapy/methods , Exercise Tolerance/drug effects , Facilitated Diffusion/drug effects , Adolescent , Adult , Blood Gas Analysis/methods , Breathing Exercises/methods , Bronchodilator Agents/administration & dosage , Cross-Over Studies , Cystic Fibrosis/diagnosis , Cystic Fibrosis/metabolism , Cystic Fibrosis/physiopathology , Cystic Fibrosis/therapy , Exercise Test/methods , Exercise Tolerance/physiology , Facilitated Diffusion/physiology , Female , Humans , Male , Nitric Oxide/metabolism , Spirometry/methods , Treatment Outcome
2.
Free Radic Biol Med ; 53(2): 305-13, 2012 Jul 15.
Article in English | MEDLINE | ID: mdl-22569413

ABSTRACT

Many natural products exhibit anti-inflammatory activity by suppressing excessive nitric oxide (NO) production by inducible NO synthase (iNOS). The maritime pine bark extract Pycnogenol has been formerly shown to decrease nitrite generation, taken as an index for NO, but so far it was not clear which constituent of the complex flavonoid mixture mediated this effect. The purpose of this study was to elucidate whether the in vivo generated Pycnogenol metabolite M1 (δ-(3,4-dihydroxyphenyl)-γ-valerolactone) displayed any activity in the context of induction of iNOS expression and excessive NO production. For the first time we show that M1 inhibited nitrite production (IC(50) 1.3 µg/ml, 95% CI 0.96-1.70) and iNOS expression (IC(50) 3.8 µg/ml, 95% CI 0.99-14.35) in a concentration-dependent fashion. This exemplifies bioactivation by metabolism because the M1 precursor molecule catechin is only weakly active. However, these effects required application of M1 in the low-micromolar range, which was not consistent with concentrations previously detected in human plasma samples after ingestion of maritime pine bark extract. Thus, we investigated a possible accumulation of M1 in cells and indeed observed high-capacity binding of this flavonoid metabolite to macrophages, monocytes, and endothelial cells. This binding was distinctly decreased in the presence of the influx inhibitor phloretin, suggesting the contribution of a facilitated M1 transport into cells. In fact, intracellular accumulation of M1 could explain why in vivo bioactivity can be observed with nanomolar plasma concentrations that typically fail to exhibit measurable activity in vitro.


Subject(s)
Catechols/pharmacology , Flavonoids/chemistry , Nitric Oxide Synthase Type II/antagonists & inhibitors , Pinus/chemistry , Plant Bark/chemistry , Plant Extracts/chemistry , Animals , Biotransformation , Catechin/metabolism , Cells, Cultured , Dose-Response Relationship, Drug , Endothelial Cells/drug effects , Endothelial Cells/metabolism , Facilitated Diffusion/drug effects , Flavonoids/pharmacology , Gene Expression/drug effects , Humans , Macrophages/drug effects , Macrophages/metabolism , Mice , Monocytes/drug effects , Monocytes/metabolism , Nitric Oxide Synthase Type II/genetics , Nitrites/analysis , Phloretin/pharmacology , Plant Extracts/pharmacology
3.
J Cell Physiol ; 227(11): 3693-700, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22378222

ABSTRACT

Vascular endothelial growth factor A (VEGF-A) is a promoter of neovascularization and thus a popular therapeutic target for diseases involving excessive growth of blood vessels. In this study, we explored the potential of the disaccharide sucrose octasulfate (SOS) to alter VEGF165 diffusion through Descemet's membrane. Descemet's membranes were isolated from bovine eyes and used as a barrier between two chambers of a diffusion apparatus to measure VEGF transport. Diffusion studies revealed a dramatic increase in VEGF165 transport in the presence of SOS, with little diffusion of VEGF165 across the membrane over a 10-h time course in the absence of SOS. Diffusion studies with VEGF121, a non-heparin binding variant of VEGF, showed robust diffusion with or without SOS. To determine a possible mechanism, we measured the ability of SOS to inhibit VEGF interactions with extracellular matrix (ECM), using cell-free and cell surface binding assays. Binding studies showed SOS had no effect on VEGF165 binding to either heparin-coated plates or endothelial cell surfaces at less than mg/ml concentrations. In contrast, we show that SOS inhibited VEGF165 binding to fibronectin in a dose dependent manner and dramatically accelerated the rate of release of VEGF165 from fibronectin. SOS also inhibited the binding of VEGF165 to fibronectin-rich ECM deposited by vascular smooth muscle cells. These results suggest that fibronectin-rich extracellular matrices serve as barriers to VEGF165 diffusion by providing a network of binding sites that can trap and sequester the protein. Since the content of Descemet's membrane is typical of many basement membranes it is possible that they serve throughout the body as formidable barriers to VEGF165 diffusion and tightly regulate its bioavailability and distribution within tissues.


Subject(s)
Descemet Membrane , Facilitated Diffusion/drug effects , Sucrose/analogs & derivatives , Vascular Endothelial Growth Factor A/metabolism , Animals , Cattle , Cells, Cultured , Descemet Membrane/drug effects , Descemet Membrane/metabolism , Diffusion Chambers, Culture , Extracellular Matrix/chemistry , Extracellular Matrix/metabolism , Fibronectins/chemistry , Fibronectins/metabolism , Humans , Muscle, Smooth, Vascular/cytology , Muscle, Smooth, Vascular/metabolism , Protein Binding/drug effects , Sucrose/chemistry , Sucrose/pharmacology , Vascular Endothelial Growth Factor A/chemistry
4.
Biol Reprod ; 85(4): 834-47, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21677305

ABSTRACT

The permeability of cells is important for cryopreservation. Previously, we showed in mice that the permeability to water and cryoprotectants of oocytes and embryos at early cleavage stages (early embryos) is low because these molecules move across the plasma membrane predominantly by simple diffusion through the lipid bilayer, whereas permeability of morulae and blastocysts is high because of a water channel, aquaporin 3 (AQP3). In this study, we examined the pathways for the movement of water and cryoprotectants in bovine oocytes/embryos and the role of AQP3 in the movement by determining permeability, first in intact bovine oocytes/embryos, then in bovine morulae with suppressed AQP3 expression, and finally in mouse oocytes expressing bovine AQP3. Results suggest that water moves through bovine oocytes and early embryos slowly by simple diffusion, as is the case in mice, although channel processes are also involved in the movement. On the other hand, water appears to move through morulae and blastocysts predominantly by facilitated diffusion via channels, as in mice. Like water, cryoprotectants appear to move through bovine oocytes/early embryos mostly by simple diffusion, but channel processes could also be involved in the movement of glycerol and ethylene glycol, unlike that in mice. In bovine morulae, although glycerol and ethylene glycol would move predominantly by facilitated diffusion, mostly through AQP3, as in mice, dimethylsulfoxide appears to move predominantly by simple diffusion, unlike in mice. These results indicate that permeability-related properties of bovine oocytes/embryos are similar to those of mouse oocytes/embryos, but species-specific differences do exist.


Subject(s)
Aquaporin 3/metabolism , Blastocyst , Cell Size/drug effects , Cryopreservation , Cryoprotective Agents/pharmacology , Fluid Shifts/drug effects , Oocytes , Animals , Aquaporin 3/genetics , Blastocyst/drug effects , Blastocyst/metabolism , Cattle , Cryoprotective Agents/metabolism , Cryoprotective Agents/pharmacokinetics , Diffusion/drug effects , Ectogenesis , Facilitated Diffusion/drug effects , Fertilization in Vitro , Gene Silencing , Hypertonic Solutions , In Vitro Oocyte Maturation Techniques , Mice , Mice, Inbred ICR , Morula/drug effects , Morula/metabolism , Morula/pathology , Oocytes/drug effects , Oocytes/metabolism , Oocytes/pathology , Permeability/drug effects , Recombinant Proteins/metabolism , Species Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...